Overview

  • Product nameAnti-Met (c-Met) antibody
    See all Met (c-Met) primary antibodies
  • Description
    Rabbit polyclonal to Met (c-Met)
  • Tested applicationsICC/IF, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    A synthetic peptide from C terminus of human Met (c-Met) protein

  • Positive control
    • A431 cells; Paraffin embedded human breast and ovarian carcinoma tissues.

Properties

Applications

Our Abpromise guarantee covers the use of ab74217 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use at an assay dependent concentration. PubMed: 24626333
IHC-P 1/50. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
WB Use a concentration of 2 - 4 µg/ml. Predicted molecular weight: 156 kDa.

Target

  • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
  • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
    Note=Defects in MET may be associated with gastric cancer.
    Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
    Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
    Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
    Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
    Contains 3 IPT/TIG domains.
    Contains 1 protein kinase domain.
    Contains 1 Sema domain.
  • DomainThe kinase domain is involved in SPSB1 binding.
  • Post-translational
    modifications
    Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • AUTS9 antibody
    • c met antibody
    • cmet antibody
    • D249 antibody
    • Hepatocyte growth factor receptor antibody
    • Hepatocyte growth factor receptor Precursor antibody
    • HGF antibody
    • HGF receptor antibody
    • HGF SF receptor antibody
    • HGF/SF receptor antibody
    • HGFR antibody
    • MET antibody
    • Met proto oncogene tyrosine kinase antibody
    • Met proto-oncogene (hepatocyte growth factor receptor) antibody
    • Met proto-oncogene antibody
    • Met protooncogene antibody
    • MET_HUMAN antibody
    • Oncogene MET antibody
    • Par4 antibody
    • Proto-oncogene c-Met antibody
    • RCCP2 antibody
    • Renal cell carcinoma papillary 2 gene antibody
    • Scatter factor receptor antibody
    • SF receptor antibody
    • Tyrosine-protein kinase Met antibody
    see all

Anti-Met (c-Met) antibody images

  • ab74217 at 1/50 dilution staining Met (c-Met) in human ovarian carcinoma by Immunohistochemistry, Formalin-fixed, Paraffin-embedded tissue.

References for Anti-Met (c-Met) antibody (ab74217)

This product has been referenced in:
  • Labsch S  et al. Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells. Int J Oncol 44:1470-80 (2014). ICC/IF . Read more (PubMed: 24626333) »

See 1 Publication for this product

Product Wall

Thank you for contacting us.

I have pasted the link to Human Protein Atlas database which shows MET positive staining of various human tissue sections. The red colour represents high staining. You can select positive control section based on...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"